Clinical Trial Update: Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib in metastatic renal cell carcinoma with brain metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Renal Cell Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED